Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I

Oral Diseases

Volumn 3, Issue SUPPL. 1, 1997, Pages

  Shugars, D C ^a   Sauls, D L ^b   Weinberg, J B ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anti viral; HIV; Saliva; Secretory leukocyte protease inhibitor

Indexed keywords

SALIVA PROTEIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

CONFERENCE PAPER; CONTROLLED STUDY; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; SALIVA ANALYSIS; VIRUS INFECTIVITY; VIRUS STRAIN; VIRUS TRANSMISSION;

EID: 0030903020     PISSN: 1354523X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1601-0825.1997.tb00379.x     Document Type: Conference Paper

References (8)

1. Adachi A, Gendelman HE, S Koenig et al (1986). Production of acquired immunodeficiency syndrome-associated retrovirus in human and non-human cells transfected with an infectious molecular clone. J Virol 59: 284-291.
2. Asjo B, Cefai D, Debre P et al (1993). A novel mode of human immunodeficiency virus type-1 (HIV-1) activation: ligation of CD28 alone induces HIV-1 replication in naturally infected lymphocytes. J Virol 67: 4395-4398.
3. Goff S, Triktman P, Baltimore D (1981). Isolation and properties of moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase. J Virol 38: 239-248.
4. Malamud D, Freidman HM (1993). HIV in the oral cavity: virus, viral inhibitory activity, and antiviral antibodies: A review. Crit Rev Oral Biol Med 4: 461-466.
5. McNeely TB. Dealy M, Dripps DJ et al (1995). Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-HIV-1 activity in vitro. J Clin Invest 96: 456-464.
6. Rice WG, Weiss SJ (1990). Regulation of proteolysis at the neutrophil-substrate interface by secretory leukoprotease inhibitor. Science 249: 178-191.
7. Shugars DC, McNeely TB, Eisenberg SP et al (1996). Secretory leukocyte protease inhibitor targets an early event in HIV infection. J Dem Res 75: 114.
8. Tomoova S, Cutruzzola F, Barra D et al (1994). Selective oxidation of methionyl residues in the human recombinant secretory leukocyte proteinase inhibitor: Effect on the inhibitory binding properties. J Mol Recognition 7: 31-34.